Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Makes Its M&A Move; Hospira Will Be More Of A Bolt-On, Read Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will buy the sterile-injectables specialist Hospira for $17 billion including debt, marking its first large-scale M&A since the company failed in its bid to buy AstraZeneca last year. The deal will expand Pfizer’s Global Established Pharmaceutical business and bolster its biosimilar portfolio.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts